<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209219</url>
  </required_header>
  <id_info>
    <org_study_id>Z171100001017217</org_study_id>
    <nct_id>NCT03209219</nct_id>
  </id_info>
  <brief_title>Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis</brief_title>
  <official_title>Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet`s Disease Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a
      and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral
      glucocorticosteroid in patients with refractory Behçet`s uveitis (BDU). Half of the
      participants will receive IFNα2a while the other half will receive CsA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description: Both CsA and IFNα2a have been shown to be effective for long-term
      control of BDU, however, randomized prospective comparative studies are scarce, particularly
      in East Asian populations. Our preliminary data gave us the impression that IFNα2a might be
      more effectiveness than CsA in long-term control of refractory BDU, and this study aimed to
      compare their effectiveness and safety profiles in a well-designed prospective study.
      Refractory BDU is defined as relapse of posterior or pan- uveitis with at least 10mg daily
      prednisone (or equivalent) and one traditional immunomodulatory treatment (IMT) agents. The
      acute attack is controlled with large dose oral corticosteroid (60mg daily prednisone) for 4
      weeks, and then the patients are randomly assigned to the IFN arm and the CsA arm, in which
      patients are treated with IFNα2a (3×10^6 IU qd for 4 weeks and qod thereafter) and CsA (100mg
      bid), respectively, along with a fixed tapering regimen of corticosteroid. Patients were
      followed up until relapse, or for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse rate</measure>
    <time_frame>within the 12-month follow-up period</time_frame>
    <description>relapse of posterior or pan-uveitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity of relapse using the BOS24</measure>
    <time_frame>within the 12-month follow-up period</time_frame>
    <description>Score of ocular inflammation using the Behcet disease ocular attack score 24 (BOS24)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Behçet Disease</condition>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Interferon Alpha 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with oral CsA 100mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon Alfa-2A</intervention_name>
    <description>3×10^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter</description>
    <arm_group_label>Interferon Alpha 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Pill</intervention_name>
    <description>100mg， oral, bid</description>
    <arm_group_label>Cyclosporine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory BDU patients fulfilling the International Criteria for Behçet`s disease
             (ICBD) published in 2013 with recent recurrence of pan- or posterior uveitis;

          -  The patient should be on ≥10mg/d oral prednisone or equivalent with at least one of
             the following IMT agents: cyclophosphamide≥50mg/d, CsA≥100mg/d, azathioprine≥50mg/d,
             methotrexate≥15mg/w, mycophenolate≥1000mg/d, tacrolimus≥2mg/d.

        Exclusion Criteria:

          -  Previous treatment with interferon-α;

          -  Pregnancy, breast feeding women;

          -  Malignancy;

          -  Renal impairment (creatinine &gt; 1.5 mg/dl);

          -  Uncontrolled hypertension or diabetes;

          -  Depression or other psychic disorders;

          -  History of acute or chronic inflammatory joint or autoimmune disease;

          -  Patients with severe extra-ocular involvement other than oral/genital ulcer and skin
             involvement;

          -  Organ or bone marrow transplant recipient, cardiac failure &gt; NYHA III;

          -  Acute liver disease with ALT or SGPT 2x above normal;

          -  White blood cell count &lt; 3500/mm^3;

          -  Platelet count &lt; 100000/mm^3;

          -  Hgb &lt; 8.5g/dl;

          -  T-SPOT TB: ≥200 SFCs per 10^6 PBMC;

          -  Active peptic ulcer, systemic or local infection, moderate to severe osteoporosis or
             other contraindications of large dose corticosteroids;

          -  Previous intolerance to CsA;

          -  Other severe ocular diseases or intraocular surgery within 3 months;

          -  Media opacity precluding a clear view of the fundus;

          -  Positive screen test for HBV, HCV, HIV infection or syphilis;

          -  Body weight &lt;45 kg;

          -  Alcohol abuse or drug abuse;

          -  Mental impairment;

          -  Uncooperative attitude.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meifen Zhang, MD</last_name>
    <phone>+86-10-69156351</phone>
    <email>meifen_zhang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chan Zhao, MD</last_name>
    <phone>+86-13810454083</phone>
    <email>zhaochanmail@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meifen Zhang, MD</last_name>
      <phone>+86-10-69156351</phone>
      <email>meifen_zhang@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chan Zhao, MD</last_name>
      <phone>+86-10-69156351</phone>
      <email>zhaochanmail@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Meifen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Meifen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>effectiveness, safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

